MaxCyte Inc (LON:MXCT) CEO Doug Doerfler sat down with Proactive Investors' Christine Corrado at the Bio Investor Forum in San Francisco.
Over the summer, the US FDA gave the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours.
Two weeks ago, the company began dosing its first patient.
Price: 117.5 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...
